Remember to specify ES – it is different than original formula Megace^®*

For your AIDS patients who are experiencing unintended weight loss, specify Megace ES for its differences over original formula Megace^®.*

Megace ES is better absorbed

• Megace ES has improved bioavailability in the unfed condition vs. original formula Megace*^† and equivalent bioavailability in the fed condition¹

• The fed condition is achieved by subjects eating a high-calorie (800-1000 calories) and high-fat (approximately 50% of total calories) meal¹⁶

An FDA example meal shown at right is 2 eggs fried in butter, 2 strips of bacon, 2 slices of toast with butter, 4 ounces of hash brown potatoes, and 8 ounces of whole milk.¹⁶

• Megace ES offers improved bioavailability in the unfed condition vs. original formula Megace*^†1

• There was comparable bioavailability between Megace ES and original formula Megace in the fed condition¹

Weight Gain Evaluated in the Pilot Study¹⁸

The weight gain associated with Megace ES and Megace was evaluated in patients with HIV-associated unintended weight loss.

• This trial was conducted as a pilot study using a concentrated suspension of 575 mg/5mL megestrol acetate. Megace ES is available as megestrol acetate 125 mg per mL oral suspension. The initial recommended dose of Megace ES is 625 mg/5 mL

• Randomized, open-label, multicenter pilot study that enrolled 63 AIDS patients. Patients received either Megace ES (575 mg/5 mL) or Megace (800 mg/20 mL) once daily in the morning for 12 weeks

• Those patients receiving megestrol acetate oral suspension 800 mg/20 mL gained an average of 6% of their baseline weight over 12 weeks (7.7lbs)¹⁸

• Safety was similar for each arm of the trial

Consider Megace ES to help your patients

• Increase their appetite

• Gain weight

• Improve their sense of well-being¹

*Megestrol acetate oral suspension.

^†Clinical significance unknown.